Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India · Delayed Price · Currency is INR | Market Cap | 4.51T +9.6% |
| Revenue (ttm) | 616.31B +12.1% |
| Net Income | 109.66B +4.9% |
| EPS | 45.71 +4.9% |
| Shares Out | 2.40B |
| PE Ratio | 41.13 |
| Forward PE | 32.33 |
| Dividend | 16.00 (0.85%) |
| Ex-Dividend Date | Jul 7, 2026 |
| Volume | 2,322,863 |
| Open | 1,887.00 |
| Previous Close | 1,885.00 |
| Day's Range | 1,869.80 - 1,915.00 |
| 52-Week Range | 1,583.70 - 2,046.90 |
| Beta | 0.13 |
| Analysts | Buy |
| Price Target | 2,111.94 (+12.34%) |
| Earnings Date | Oct 30, 2026 |
About NSE:SUNPHARMA
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It ... [Read more]
Financial Performance
In fiscal year 2026, NSE:SUNPHARMA's revenue was 584.62 billion, an increase of 11.19% compared to the previous year's 525.78 billion. Earnings were 114.79 billion, an increase of 5.04%.
Financial StatementsAnalyst Summary
According to 34 analysts, the average rating for SUNPHARMA stock is "Buy." The 12-month stock price target is ₹2,112, which is an increase of 12.34% from the latest price.
News
Sun Pharmaceutical Industries Transcript: Q2 26/27
Q2 revenue rose 11.8% YoY, led by India and innovative medicines, while lenalidomide erosion pressured U.S. sales. FY27 guidance is unchanged, and R&D investment is expected to catch up in H2.
Sun Pharmaceutical Industries Quarterly report: Q2 2027
Sun Pharmaceutical Industries has published its Q2 2027 quarterly earnings report on October 30, 2026.
Sun Pharmaceutical Industries Slides: Q2 2027
Sun Pharmaceutical Industries has posted slides in relation to its Q2 2027 quarterly earnings report, which was published on October 30, 2026.
India orders Sun Pharma to halt eye-care drug production at plant after quality lapses
Indian drug regulators ordered Sun Pharmaceutical Industries to stop manufacturing, selling and distributing ophthalmic products made at its Assam facility after finding failure in its quality managem...
Sun Pharma's profit falls on Organon deal charge; specialty drug sales remain strong
India's Sun Pharmaceutical Industries reported a drop in second-quarter profit on Friday, as a one-time charge largely tied to its planned acquisition of Organon weighed, though demand for specialty m...
Sun Pharma's Ilumya Wins FDA Approval For Active Psoriatic Arthritis
(RTTNews) - Sun Pharmaceutical Industries Ltd. (SUNPHARMA.NS) said Friday the U.S. Food and Drug Administration (FDA) approved Ilumya for adults with active psoriatic arthritis, expanding its use beyo...
Sun Pharma Reports Durable UNLOXCYT Responses In Advanced Skin Cancer
(RTTNews) - Sun Pharmaceutical Industries (SUNPHARMA) announced updated long-term data for UNLOXCYT (cosibelimab-ipdl) in advanced cutaneous squamous cell carcinoma at ESMO 2026.
Sun Pharma's UNLOXCYT Added As NCCN Category 2A Option For Locally Advanced Skin Cancer
(RTTNews) - Sun Pharmaceutical Industries Ltd. (SUNPHARMA, 524715) announced that UNLOXCYT (cosibelimab-ipdl) has been added to a National Comprehensive Cancer Network (NCCN) Category 2A recommended o...
Indoco Remedies Share Price Quietly Does Something Most Mid-Cap Pharma Stocks Won’t
Financial headlines are not typically dominated by Indoco Remedies. Its market capitalization of about ₹2,200 crore keeps it firmly in mid-cap territory, where stocks can move sharply on relatively mo...
India's Sun Pharmaceuticals to consider raising $1.55 billion via debentures
India's Sun Pharmaceuticals on Wednesday said it would consider raising up to 150 billion rupees ($1.55 billion) via non-convertible debentures at its board meeting on October 12.
Sun Pharma Reports Two-Year LEQSELVI Data In Severe Alopecia Areata
(RTTNews) - Thursday, Sun Pharmaceutical Industries Limited (SUNPHARMA) reported two-year safety and efficacy data for LEQSELVI (deuruxolitinib) in adults with severe alopecia areata at the 2026 Europ...
Mayne Pharma, Sun Pharma Settle IMVEXXY Patent Case, Generic Entry Set For 2032
(RTTNews) - Mayne Pharma Group Ltd. (MYX.AX) announced that Sun Pharmaceutical Industries Ltd. (SUNPHARMA.NS) has agreed to settle U.S. Paragraph IV patent litigation concerning IMVEXXY and its associ...
Mayne Pharma Settles IMVEXXY Patent Litigation With Sun Pharma
(RTTNews) - Mayne Pharma Group Limited (MYX.AX) has reached settlement with Sun Pharmaceutical Industries Ltd. (SUNPHARMA.NS), resolving the Paragraph 1V patent litigation concerning IMVEXXY (estradio...
India's Sun Pharma plans $1 billion local debt sale for loan takeout, sources say
India's Sun Pharmaceutical Industries is planning to raise around 100 billion rupees ($1.04 billion) via a rupee-denominated debt sale to partly fund a bridge loan it took to acquire US healthcare fir...
Sun Pharma Launches Osmotic Delivery Formulation Of Methylphenidate In Canada
(RTTNews) - Sun Pharmaceutical Industries (SUNPHARMA.NS) announced the commercial availability of Taro-Methylphenidate ER for Canadian patients in Ontario and Quebec. Taro-Methylphenidate ER is the on...
Sun Pharma Launches Taro-Methylphenidate ER, Generic Alternative To Concerta
(RTTNews) - Sun Pharmaceutical Industries Ltd. (SUNPHARMA), a pharmaceutical company, on Thursday announced the commercial availability of Taro-Methylphenidate ER for patients in Ontario and Quebec, C...
Sun Pharma Backs The First Standardized U.S. Treatment Recommendations For Severe Alopecia Areata
(RTTNews) - Sun Pharmaceutical Industries Ltd. (SUNPHARMA.NS) said that it supports the first standardized U.S. treatment recommendations for adults with severe alopecia areata (AA) have been publishe...
Cipher Pharmaceuticals Secures Court Confirmation Of Arbitration Award
(RTTNews) - Cipher Pharmaceuticals Inc. (CPH.TO) has received a favorable ruling from the New York federal court, which denied Sun Pharmaceutical Industries' petition to vacate portions of an arbitrat...
Sun Pharma offers US cheaper drug supply
India Business News: New Delhi: Facing the threat of potential tariffs, India’s largest drug firm, Sun Pharma has offered Most Favoured Nation (MFN) pricing to US Medicaid.
Sun Pharmaceutical Industries Slides: Investor presentation
Sun Pharmaceutical Industries has posted slides in relation to its latest quarterly earnings report, which was published on September 1, 2026.
India's Sun Pharma, 8 Drugmakers Sign Pricing Deals With Team Trump
The deal comes amid Team Trump's pressure on midsize companies to fall in line with its pricing regime, as it expands its most-favoured-nation (MFN) pricing push.
Sun Pharma withdraws 11 eye medicines
India News: NEW DELHI: Eleven ophthalmic products marketed by Sun Pharma have been withdrawn after the company's distribution arm directed retailers to stop furth.
Sun Pharmaceutical Industries Transcript: Q1 26/27
Q1 FY 2027 saw 10.1% revenue growth, led by India and innovative medicines, while U.S. generics declined. Organon acquisition is on track, and Sun maintains high single-digit growth guidance for the year. Gross margin improved to 80.5% on a better product mix.
Sun Pharmaceutical Industries Quarterly report: Q1 2027
Sun Pharmaceutical Industries has published its Q1 2027 quarterly earnings report on July 31, 2026.
Sun Pharma's quarterly profit jumps on strength in specialty medicines
India's Sun Pharmaceutical Industries reported a 27% rise in first-quarter profit on Friday, driven by robust growth in its high-margin specialty medicines business as the country's largest drugmaker ...